Bristol Myers (BMY) recently announced that a late-stage study, seeking to expand the label of its cancer combination drug, Opdivo (nivolumab) and Yervoy (ipilimumab), failed to meet the primary endpoint of progression-free survival in unresectable, locally advanced stage III non-small cell lung cancer (NSCLC). The phase III CheckMate -73L study evaluated Opdivo with concurrent chemoradiotherapy (CCRT) followed by Opdivo plus Yervoycompared with CCRT followed by AstraZeneca’s (AZN) Imfinzi (durvalumab) in 9 ...